Paula M De Angelis

Summary

Affiliation: University of Oslo
Country: Norway

Publications

  1. ncbi Apoptosis and expression of Bax, Bcl-x, and Bcl-2 apoptotic regulatory proteins in colorectal carcinomas, and association with p53 genotype/phenotype
    P M De Angelis
    Norwegian National Hospital, Institute for Pathology University of Oslo, Norway
    Mol Pathol 51:254-61. 1998
  2. ncbi Prognostic significance of recurrent chromosomal aberrations detected by comparative genomic hybridization in sporadic colorectal cancer
    P M De Angelis
    Institute of Pathology, Norwegian National Hospital, 0027 Oslo, Norway
    Int J Colorectal Dis 16:38-45. 2001
  3. ncbi Molecular characterizations of derivatives of HCT116 colorectal cancer cells that are resistant to the chemotherapeutic agent 5-fluorouracil
    Paula M De Angelis
    Institute of Pathology, Norwegian National Hospital, N 0027 Oslo, Norway
    Int J Oncol 24:1279-88. 2004
  4. ncbi Comparison of gene expression in HCT116 treatment derivatives generated by two different 5-fluorouracil exposure protocols
    Paula M De Angelis
    Institute of Pathology, Rikshospitalet, 0027 Oslo, Norway
    Mol Cancer 3:11. 2004
  5. ncbi Cellular response to 5-fluorouracil (5-FU) in 5-FU-resistant colon cancer cell lines during treatment and recovery
    Paula M De Angelis
    Institute of Pathology, Section for Molecular Chemoresistance, Rikshospitalet Radiumhospitalet HF, Oslo, Norway
    Mol Cancer 5:20. 2006
  6. ncbi DNA damage signaling in response to 5-fluorouracil in three colorectal cancer cell lines with different mismatch repair and TP53 status
    Birgitte L Adamsen
    Department of Pathology, Clinic for Diagnostics and Intervention, Oslo University Hospital, Rikshospitalet, Oslo, Norway
    Int J Oncol 39:673-82. 2011
  7. ncbi Cellular response to irinotecan in colon cancer cell lines showing differential response to 5-fluorouracil
    Kristiane Haug
    The Pathology Clinic, Rikshospitalet Medical Center, 0027 Oslo, Norway
    Anticancer Res 28:583-92. 2008
  8. ncbi Cellular response to chemoradiotherapy, radiotherapy and chemotherapy in two colorectal cancer cell lines
    Birgitte Lid Adamsen
    The Pathology Clinic, Rikshospital University Hospital, 0027 Oslo, Norway
    Radiat Res 171:562-71. 2009
  9. ncbi Correlation between reduced expression of the spindle checkpoint protein BubR1 and bad prognosis in tonsillar carcinomas
    Kirsten Hannisdal
    Department of Otorhinolaryngology Head and Neck Surgery, Oslo University Hospital, Rikshospitalet, Oslo, Norway
    Head Neck 32:1354-62. 2010
  10. ncbi Chromosomal 20q gain in the DNA diploid component of aneuploid colorectal carcinomas
    Paula M De Angelis
    The Pathology Clinic, University of Oslo, Rikshospitalet Radiumhospitalet Medical Center, 0027 Oslo, Norway
    Int J Cancer 120:2734-8. 2007

Collaborators

Detail Information

Publications12

  1. ncbi Apoptosis and expression of Bax, Bcl-x, and Bcl-2 apoptotic regulatory proteins in colorectal carcinomas, and association with p53 genotype/phenotype
    P M De Angelis
    Norwegian National Hospital, Institute for Pathology University of Oslo, Norway
    Mol Pathol 51:254-61. 1998
    ..The p53 genotypes/phenotypes and BAX genotypes were also determined, and possible associations of these with apoptosis and/or with expression of the different apoptotic regulatory proteins were studied...
  2. ncbi Prognostic significance of recurrent chromosomal aberrations detected by comparative genomic hybridization in sporadic colorectal cancer
    P M De Angelis
    Institute of Pathology, Norwegian National Hospital, 0027 Oslo, Norway
    Int J Colorectal Dis 16:38-45. 2001
    ..Loss of chromosome arm 1p, 4q, 8p, 14q, or 18q or gain of chromosome arm 20q thus results in shortened survival times in colorectal cancer patients. 1p loss and 8p loss were shown to be independent predictors of poor prognosis...
  3. ncbi Molecular characterizations of derivatives of HCT116 colorectal cancer cells that are resistant to the chemotherapeutic agent 5-fluorouracil
    Paula M De Angelis
    Institute of Pathology, Norwegian National Hospital, N 0027 Oslo, Norway
    Int J Oncol 24:1279-88. 2004
    ..Development of 5-FU resistance thus appears to encompass deregulation of apoptosis-, proliferation-, DNA repair-, and metastasis-associated regulatory pathways...
  4. ncbi Comparison of gene expression in HCT116 treatment derivatives generated by two different 5-fluorouracil exposure protocols
    Paula M De Angelis
    Institute of Pathology, Rikshospitalet, 0027 Oslo, Norway
    Mol Cancer 3:11. 2004
    ....
  5. ncbi Cellular response to 5-fluorouracil (5-FU) in 5-FU-resistant colon cancer cell lines during treatment and recovery
    Paula M De Angelis
    Institute of Pathology, Section for Molecular Chemoresistance, Rikshospitalet Radiumhospitalet HF, Oslo, Norway
    Mol Cancer 5:20. 2006
    ....
  6. ncbi DNA damage signaling in response to 5-fluorouracil in three colorectal cancer cell lines with different mismatch repair and TP53 status
    Birgitte L Adamsen
    Department of Pathology, Clinic for Diagnostics and Intervention, Oslo University Hospital, Rikshospitalet, Oslo, Norway
    Int J Oncol 39:673-82. 2011
    ..DNA repair and cell cycle responses to 5-FU-induced DNA damage were distinctly affected by MMR and TP53 (role in BER/NER) functionalities, but MMR deficiency especially seemed to confer less overall sensitivity to 5-FU...
  7. ncbi Cellular response to irinotecan in colon cancer cell lines showing differential response to 5-fluorouracil
    Kristiane Haug
    The Pathology Clinic, Rikshospitalet Medical Center, 0027 Oslo, Norway
    Anticancer Res 28:583-92. 2008
    ..Cross-resistance to both drugs may however be a potential clinical problem. The cellular response to CPT-11 was investigated in two human colon cancer cell lines that demonstrate a differential response to 5-FU...
  8. ncbi Cellular response to chemoradiotherapy, radiotherapy and chemotherapy in two colorectal cancer cell lines
    Birgitte Lid Adamsen
    The Pathology Clinic, Rikshospital University Hospital, 0027 Oslo, Norway
    Radiat Res 171:562-71. 2009
    ....
  9. ncbi Correlation between reduced expression of the spindle checkpoint protein BubR1 and bad prognosis in tonsillar carcinomas
    Kirsten Hannisdal
    Department of Otorhinolaryngology Head and Neck Surgery, Oslo University Hospital, Rikshospitalet, Oslo, Norway
    Head Neck 32:1354-62. 2010
    ..The aim of the present study was to examine their possible impact on prognosis in tonsillar carcinomas and their relation to clinical variables, the prevalence of human papillomavirus (HPV), p53 status, and Ki-67 positivity...
  10. ncbi Chromosomal 20q gain in the DNA diploid component of aneuploid colorectal carcinomas
    Paula M De Angelis
    The Pathology Clinic, University of Oslo, Rikshospitalet Radiumhospitalet Medical Center, 0027 Oslo, Norway
    Int J Cancer 120:2734-8. 2007
    ..2 and by KRAS mutations, but not by TP53 deletions or losses of large chromosomal regions such as 4q, 8p and 18q...
  11. ncbi Aneuploidy is associated with TP53 expression but not with BRCA1 or TERT expression in sporadic colorectal cancer
    Aasa R Schjølberg
    The Pathology Clinic, Oslo University Hospital Rikshospitalet, 0027 Oslo, Norway
    Anticancer Res 29:4381-7. 2009
    ..Defective expression of genes involved in mitotic chromosome segregation (e.g. AURKA, BUB1B), DNA damage response (e.g. TP53, BRCA1), and telomere function (e.g. TERT) may play a role in the development of tumor aneuploidy...
  12. ncbi Keratoacanthomas frequently show chromosomal aberrations as assessed by comparative genomic hybridization
    Ole Petter F Clausen
    Institute and Department of Pathology, University of Oslo, Rikshospitalet, Oslo, Norway
    J Invest Dermatol 119:1367-72. 2002
    ....